Braidwell LP Has $30.71 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Braidwell LP lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 57.4% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 168,691 shares of the company’s stock after buying an additional 61,512 shares during the quarter. Braidwell LP’s holdings in Krystal Biotech were worth $30,707,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Segall Bryant & Hamill LLC raised its stake in Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares in the last quarter. Principal Financial Group Inc. raised its stake in Krystal Biotech by 1,972.0% in the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after purchasing an additional 117,510 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Public Sector Pension Investment Board acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at approximately $10,037,000. Finally, Rhumbline Advisers raised its position in shares of Krystal Biotech by 123.3% in the 2nd quarter. Rhumbline Advisers now owns 71,685 shares of the company’s stock valued at $13,164,000 after buying an additional 39,586 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Up 0.2 %

Shares of Krystal Biotech stock opened at $196.91 on Friday. Krystal Biotech, Inc. has a 12-month low of $99.00 and a 12-month high of $219.34. The company has a market cap of $5.66 billion, a price-to-earnings ratio of 111.25 and a beta of 0.82. The company’s 50-day moving average price is $180.23 and its 200-day moving average price is $183.28.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period last year, the firm posted ($0.67) earnings per share. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on KRYS shares. Stifel Nicolaus boosted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Evercore ISI upped their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Chardan Capital boosted their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th. Finally, William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Buy” and a consensus price target of $202.29.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).